貝瑞基因(000710.SZ):子公司與首都醫科大學附屬北京兒童醫院簽署《項目成果轉化合作框架協議》
格隆匯4月15日丨貝瑞基因(000710.SZ)公佈,公司之全資子公司北京貝瑞和康生物技術有限公司(簡稱“北京貝瑞”或“乙方”)與首都醫科大學附屬北京兒童醫院(簡稱“北京兒童醫院”或“甲方”)簽訂了《項目成果轉化合作框架協議》。鑑於甲乙雙方於2022年11月共同申報了由北京市科學技術委員會、中關村科技園區管理委員會委託的“首都臨牀特色診療技術研究及轉化應用”項目“新生兒功能性出生缺陷的早篩早診關鍵技術研究及產品研發”課題(課題號:Z221100007422017),並承擔項目成果轉化的任務。雙方爲推動項目成果的臨牀轉化和商業化應用,本着平等互利、優勢互補、協同發展的原則,經友好協商,達成合作框架協議。
推動技術成果轉化:將甲方的新生兒功能性出生缺陷早篩早診技術成果“兒科遺傳病一體化平臺V1.0”進行有效轉化,以新生兒篩查作爲切入點,利用人工智能等技術,將遺傳諮詢、健康管理、預防幹預等服務延伸至兒童期,共同開發出具有臨牀應用價值和市場競爭力的覆蓋胎兒、新生兒、嬰幼兒、學齡前兒童的全生命週期健康管理體系,形成可複製、可推廣的區域兒童健康管理新模式。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.